ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactions are described elsewhere in the labeling:Hypersensitivity Reactions see Warnings and Precautions (5.1) . The most common adverse reactions that occurred in >=1 patient were otorrhea, excessive granulation tissue, ear infection, ear pruritus, tympanic membrane disorder, auricular swelling and balance disorder 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Xspire Pharma at 1-888-252-3901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In clinical trials, 224 patients with AOMT were treated with Ciprofloxacin and Fluocinolone Acetonide Otic Solution for median duration of days. All the patients received at least one dose of Ciprofloxacin and Fluocinolone Acetonide Otic Solution. There were 220 patients who received at least one dose of ciprofloxacin (CIPRO) and 213 patients received at least one dose of fluocinolone acetonide (FLUO).The most common adverse reactions that occurred in or more patients are as follows:Table 1:Selected Adverse Reactions that Occurred in or more Patients in the Ciprofloxacin and Fluocinolone Acetonide Otic Solution GroupAdverse Reactions Selected adverse reactions that occurred in >= patient in the Ciprofloxacin and Fluocinolone Acetonide Otic Solution group derived from all reported adverse events that could be related to the study drug or the drug class. Number (%) of PatientsCiprofloxacin and Fluocinolone Acetonide Otic Solution N=224 CIPRO N=220 FLUO N=213 Otorrhea12 (5.4%)9 (4.1%)12 (5.6%)Excessive granulation tissue3 (1.3%)0 (0.0%)2 (0.9%)Ear infection2 (0.9%)3 (1.4%)1 (0.5%)Ear pruritus2 (0.9%)1 (0.5%)1 (0.5%)Tympanic membrane disorder2 (0.9%)0 (0.0%)0 (0.0%)Auricular swelling1 (0.4%)1 (0.5%)0 (0.0%)Balance disorder1 (0.4%)0 (0.0%)0 (0.0%). 6.2Postmarketing Experience. The following adverse reactions have been identified during postapproval use of ciprofloxacin and fluocinolone acetonide otic solution, 0.3% 0.025% outside the US. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Immune system disorders: allergic reaction. Infections and infestations: candidiasis. Nervous system disorders: dysgeusia, paresthesia (tingling in ears), dizziness, headache. Ear and labyrinth disorders: ear discomfort, hypoacusis, tinnitus, ear congestion. Vascular disorders: flushing. Skin and subcutaneous tissue disorders: skin exfoliation. Injury, poisoning and procedural complications: device occlusion (tympanostomy tube obstruction). Immune system disorders: allergic reaction. Infections and infestations: candidiasis. Nervous system disorders: dysgeusia, paresthesia (tingling in ears), dizziness, headache. Ear and labyrinth disorders: ear discomfort, hypoacusis, tinnitus, ear congestion. Vascular disorders: flushing. Skin and subcutaneous tissue disorders: skin exfoliation. Injury, poisoning and procedural complications: device occlusion (tympanostomy tube obstruction).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisNo long term studies of Ciprofloxacin and Fluocinolone Acetonide Otic Solution have been performed to evaluate carcinogenic potential.Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.Long-term animal studies have not been performed to evaluate the carcinogenic potential of fluocinolone acetonide.. MutagenesisEight in vitro mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below: Salmonella/Microsome Test (Negative)E. coli DNA Repair Assay (Negative) Mouse Lymphoma Cell Forward Mutation Assay (Positive)Chinese Hamster V79 Cell HGPRT Test (Negative)Syrian Hamster Embryo Cell Transformation Assay (Negative)Saccharomyces cerevisiae Point Mutation Assay (Negative) Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative) Rat Hepatocyte DNA Repair Assay (Positive)Thus, of the tests were positive, but results of the following in vivo test systems gave negative results: Rat Hepatocyte DNA Repair AssayMicronucleus Test (Mice)Dominant Lethal Test (Mice)Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide. Some corticosteroids have been found to be genotoxic.. Salmonella/Microsome Test (Negative). E. coli DNA Repair Assay (Negative) Mouse Lymphoma Cell Forward Mutation Assay (Positive). Chinese Hamster V79 Cell HGPRT Test (Negative). Syrian Hamster Embryo Cell Transformation Assay (Negative). Saccharomyces cerevisiae Point Mutation Assay (Negative) Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative) Rat Hepatocyte DNA Repair Assay (Positive). Rat Hepatocyte DNA Repair Assay. Micronucleus Test (Mice). Dominant Lethal Test (Mice). Impairment of FertilityNo reproduction toxicity studies were conducted with Ciprofloxacin and Fluocinolone Acetonide Otic Solution. Absorption of ciprofloxacin and fluocinolone acetonide following otic administration of Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the recommended dosage is negligible see Clinical Pharmacology (12.3) ].

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Ciprofloxacin is fluoroquinolone antibacterial see Microbiology (12.4) ]. Fluocinolone acetonide, corticosteroid, inhibits the local biosynthesis of prostaglandins, which explains part of its anti-inflammatory efficacy. At the cellular level, corticosteroids induce peptides called lipocortins. Lipocortins antagonize phospholipase A2, an enzyme which causes the breakdown of leukocyte lysosomal membranes to release arachidonic acid. This action decreases the subsequent formation and release of endogenous inflammatory mediators including prostaglandins, kinins, histamine, liposomal enzymes and the complement system.. 12.3 Pharmacokinetics. In two studies in children with AOMT aged >= months to 12 years, blood samples were taken in subgroups of 16 and 14 patients, at Visit (prior to the first dose) and Visit (within and hours after the last dose) respectively, to determine the plasma concentrations of ciprofloxacin and/or fluocinolone acetonide following administration of Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the recommended dosage regimen of 0.25 mL twice daily. Pharmacokinetic (PK) analysis resulted in only sample showing detectable concentration of ciprofloxacin in plasma of 3.0 mcg/L after days of treatment, and no detectable concentrations in plasma of fluocinolone acetonide were observed. However, the sample with detectable ciprofloxacin concentrations was from patient who had bilateral AOMT (protocol deviation because all patients participating in the PK study were to have unilateral otorrhea) and who received treatment in both ears with ciprofloxacin 0.3% otic solution, the active comparator.. 12.4 Microbiology. Mechanism of ActionThe bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA.. ResistanceBacterial resistance to quinolones can develop through chromosomal or plasmid-mediated mechanisms. In vitro studies demonstrated cross-resistance between ciprofloxacin and some fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. Antimicrobial ActivityCiprofloxacin has been shown to be active against most isolates of the following bacteria, both in vitro and clinically in otic infections see Indications and Usage (1) ]: Aerobic Bacteria:Gram-positive Bacteria: Staphylococcus aureus Streptococcus pneumoniae Gram-negative Bacteria: Pseudomonas aeruginosa Haemophilus influenzae Moraxella catarrhalis.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. Two phase multicenter, randomized, double-blind, active-controlled, parallel group trials were conducted in 662 pediatric patients in total (aged months to 12 years old) with AOMT, to assess the efficacy and safety of Ciprofloxacin and Fluocinolone Acetonide Otic Solution compared to ciprofloxacin otic solution and to fluocinolone acetonide otic solution (Trial and Trial 2).In both trials, the Ciprofloxacin and Fluocinolone Acetonide Otic Solution treatment arms showed significantly shorter times to cessation of otorrhea in comparison to both the ciprofloxacin and fluocinolone acetonide alone arms demonstrating the contribution of both components of Ciprofloxacin and Fluocinolone Acetonide Otic Solution. The results are presented in the table below:Table 2:Results of the Primary Endpoint: Time to Cessation of Otorrhea (Trial and Trial 2)Treatment armn.e.: not estimable because the number of censored patients was greater than the number of patients with cessation of otorrheaTrial 1Ciprofloxacin and Fluocinolone Acetonide Otic Solution (N=112) CIPRO (N=109) FLUO (N=110) Number (%) with cessation of otorrhea by Day 2288 (78.6%)73 (67.0%)53 (48.2%)Median time to cessation Kaplan-Meier median estimate censored all subjects who did not have cessation of otorrhea at the maximum time point of 22 days. (days) 3.757.69n.e.p-value vs Ciprofloxacin and Fluocinolone Acetonide Otic Solution Log-rank test stratified by age (patients younger than years versus years and older) <0.001<0.001Trial 2Ciprofloxacin and Fluocinolone Acetonide Otic Solution (N=111) CIPRO (N=112) FLUO (N=108) Number (%) with cessation of otorrhea by Day 2287 (78.4%)77 (68.8%)47 (43.5%)Median time to cessation (days) 4.946.83n.e.p-value vs Ciprofloxacin and Fluocinolone Acetonide Otic Solution 0.028<0.001.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is contraindicated in:Patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of Ciprofloxacin and Fluocinolone Acetonide Otic Solution.Viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections.. Patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of Ciprofloxacin and Fluocinolone Acetonide Otic Solution.. Viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections.. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is contraindicated in:Patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any component of Ciprofloxacin and Fluocinolone Acetonide Otic Solution. 4) Viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. 4) Patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any component of Ciprofloxacin and Fluocinolone Acetonide Otic Solution. 4) Viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. 4).

DESCRIPTION SECTION.

11 DESCRIPTION. Ciprofloxacin and Fluocinolone Acetonide Otic Solution, 0.3% 0.025% is sterile, preservative-free, clear otic solution containing the fluoroquinolone antibacterial, ciprofloxacin hydrochloride, combined with the corticosteroid, fluocinolone acetonide. Each single-dose vial contains deliverable volume of 0.25 mL solution of ciprofloxacin hydrochloride equivalent to 0.75 mg ciprofloxacin and 0.0625 mg fluocinolone acetonide. The pH of the solution ranges from 3.5 to 5.0. The inactive ingredients are polysorbate 80, glycerin, povidone K90F and water for injection.Ciprofloxacin is available as the monohydrochloride, monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its molecular formula is 17H 18FN 3O 3HClH 2O. The chemical structure of ciprofloxacin hydrochloride is:The chemical name of fluocinolone acetonide is (6,11,16)-6,9-difluoro-11,21-dihydroxy- 16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone[67-73-2]. Its molecular formula is 24H 30F 2O 6. The chemical structure of fluocinolone acetonide is:. Chemical Structure-Ciprofloxin. Chemical Structure-Fluocinolone Acetonide.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic use only. It is not for ophthalmic use, or for injection.The recommended dosage regimen is as follows:Instill the contents of one single-dose vial 0.25 mL into the affected ear canal twice daily (approximately every 12 hours) for days. Use this dosing for patients aged months of age and older.Warm the solution by holding the vial in the hand for to minutes. This is to avoid dizziness, which may result from the instillation of cold solution into the ear canal.The patient should lie with the affected ear upward, and then instill the medication.Pump the tragus times by pushing inward to facilitate penetration of the medication into the middle ear.Maintain this position for minute. Repeat, if necessary, for the opposite ear [see Instructions for Use] . Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic use only. It is not for ophthalmic use, or for injection.. Instill the contents of one single-dose vial 0.25 mL into the affected ear canal twice daily (approximately every 12 hours) for days. Use this dosing for patients aged months of age and older.. Warm the solution by holding the vial in the hand for to minutes. This is to avoid dizziness, which may result from the instillation of cold solution into the ear canal.. The patient should lie with the affected ear upward, and then instill the medication.. Pump the tragus times by pushing inward to facilitate penetration of the medication into the middle ear.. Maintain this position for minute. Repeat, if necessary, for the opposite ear [see Instructions for Use] . Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic administration only. It is not for ophthalmic use, or for injection. 2) Instill the contents of one single-dose vial (0.25 mL) into the affected ear canal twice daily for days. 2) Use this dosing regimen for patients aged months and older. 2) Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic administration only. It is not for ophthalmic use, or for injection. 2) Instill the contents of one single-dose vial (0.25 mL) into the affected ear canal twice daily for days. 2) Use this dosing regimen for patients aged months and older. 2).

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Otic Solution: Each single-dose vial of Ciprofloxacin and Fluocinolone Acetonide Otic Solution (ciprofloxacin 0.3 and fluocinolone acetonide 0.025 %) delivers 0.25 mL of solution equivalent to ciprofloxacin 0.75 mg and fluocinolone acetonide 0.0625 mg.. Otic Solution: Each single-dose vial of Ciprofloxacin and Fluocinolone Acetonide Otic Solution (ciprofloxacin 0.3 and fluocinolone acetonide 0.025 %) delivers 0.25 mL of solution equivalent to ciprofloxacin 0.75 mg and fluocinolone acetonide 0.0625 mg.

GERIATRIC USE SECTION.

8.5 Geriatric Use. Clinical studies of Ciprofloxacin and Fluocinolone Acetonide Otic Solution did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. How suppliedCiprofloxacin and Fluocinolone Acetonide Otic Solution, 0.3 %/0.025 %, is sterile, preservative-free, clear otic solution supplied in blue translucent single-dose 0.25 mL vials. Fourteen single-dose vials are packaged in protective foil pouch contained in carton (NDC 42195-128-14).. StorageStore at 20-25C (68-77F); excursions permitted to 15-30C (59-86F) [see USP Controlled Room Temperature]. Protect from light; store unused vials in pouch and discard days after opening the pouch. Do not open until ready to use. Discard vial after use.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged months and older) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is combination of ciprofloxacin, fluoroquinolone antibacterial, and fluocinolone acetonide, corticosteroid, indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged months and older) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa 1).

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Advise the patient or caregiver to read the FDA-approved patient labeling Patient Information and Instructions for Use). Administration InstructionsAdvise patients that Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic use only. It is not to be used in the eyes.Advise patients to warm the otic solution by holding the vial in the hand for to minutes before instilling it in the ear, to avoid dizziness.. Advise patients that Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for otic use only. It is not to be used in the eyes.. Advise patients to warm the otic solution by holding the vial in the hand for to minutes before instilling it in the ear, to avoid dizziness.. Hypersensitivity ReactionsAdvise patients to immediately discontinue Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the first appearance of skin rash or any other sign of hypersensitivity [see Warnings and Precautions (5.1)] Advise patients to immediately discontinue Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the first appearance of skin rash or any other sign of hypersensitivity [see Warnings and Precautions (5.1)].

INSTRUCTIONS FOR USE SECTION.

INSTRUCTIONS FOR USE CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE (sip-roh-flok-suh-sin and floo-oh-SIN-oh-lone uh-SEET-oh-nide) Otic Solution Read this Instructions for Use that comes with Ciprofloxacin and Fluocinolone Acetonide Otic Solution before you start using it and each time you get refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.Important information about Ciprofloxacin and Fluocinolone Acetonide Otic Solution: Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for use in the ear only (otic use). Do not inject Ciprofloxacin and Fluocinolone Acetonide Otic Solution or use Ciprofloxacin and Fluocinolone Acetonide Otic Solution in the eye. Use Ciprofloxacin and Fluocinolone Acetonide Otic Solution exactly as your healthcare provider tells you to use it.How should use Ciprofloxacin and Fluocinolone Acetonide Otic SolutionStep 1. You or your caregiver should wash their hands with soap and water.Step 2. Gently clean any fluid (discharge) from the outer ear using clean cloth or tissue. Do not put cotton swab or any other object in the ear canal. Step 3. Remove Ciprofloxacin and Fluocinolone Acetonide Otic Solution from the protective foil pouch. Pull apart single-dose vial of Ciprofloxacin and Fluocinolone Acetonide Otic Solution as shown, by tearing along the dotted lines (perforations) until it is fully separated.Step 4. Warm the dose of Ciprofloxacin and Fluocinolone Acetonide Otic Solution by holding the vial in your hand for to minutes. Step 5. Twist off the vial cap in the direction of the arrow as shown.Step 6. The person receiving Ciprofloxacin and Fluocinolone Acetonide Otic Solution should be on his/her side with the infected ear up as shown. Step 7. Hold the vial of Ciprofloxacin and Fluocinolone Acetonide Otic Solution in your hand and place the vial close to the ear. Let the entire dose of Ciprofloxacin and Fluocinolone Acetonide Otic Solution fall into the affected ear.Step 8. Gently press the part of the ear known as the tragus times using pumping motion as shown. This will allow the drops of Ciprofloxacin and Fluocinolone Acetonide Otic Solution to enter the middle ear. Step 9. Remain on your side with the affected ear facing upward for minute. Step 10. If your healthcare provider has told you to use Ciprofloxacin and Fluocinolone Acetonide Otic Solution in both ears, repeat Steps 2-9 for the other ear.Step 11. Safely throw away Ciprofloxacin and Fluocinolone Acetonide Otic Solution vials after use.This Instructions for Use has been approved by the Food and Drug Administration.. Ciprofloxacin and Fluocinolone Acetonide Otic Solution is for use in the ear only (otic use). Do not inject Ciprofloxacin and Fluocinolone Acetonide Otic Solution or use Ciprofloxacin and Fluocinolone Acetonide Otic Solution in the eye. Use Ciprofloxacin and Fluocinolone Acetonide Otic Solution exactly as your healthcare provider tells you to use it.. Image. Image. Image. Image. Image. Image. Image. Image. Image.

LACTATION SECTION.

8.2 Lactation. Risk SummaryCiprofloxacin and Fluocinolone Acetonide Otic Solution is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide see Clinical Pharmacology (12.3) ].

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Ciprofloxacin is fluoroquinolone antibacterial see Microbiology (12.4) ]. Fluocinolone acetonide, corticosteroid, inhibits the local biosynthesis of prostaglandins, which explains part of its anti-inflammatory efficacy. At the cellular level, corticosteroids induce peptides called lipocortins. Lipocortins antagonize phospholipase A2, an enzyme which causes the breakdown of leukocyte lysosomal membranes to release arachidonic acid. This action decreases the subsequent formation and release of endogenous inflammatory mediators including prostaglandins, kinins, histamine, liposomal enzymes and the complement system.

MICROBIOLOGY SECTION.

12.4 Microbiology. Mechanism of ActionThe bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA.. ResistanceBacterial resistance to quinolones can develop through chromosomal or plasmid-mediated mechanisms. In vitro studies demonstrated cross-resistance between ciprofloxacin and some fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. Antimicrobial ActivityCiprofloxacin has been shown to be active against most isolates of the following bacteria, both in vitro and clinically in otic infections see Indications and Usage (1) ]: Aerobic Bacteria:Gram-positive Bacteria: Staphylococcus aureus Streptococcus pneumoniae Gram-negative Bacteria: Pseudomonas aeruginosa Haemophilus influenzae Moraxella catarrhalis.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisNo long term studies of Ciprofloxacin and Fluocinolone Acetonide Otic Solution have been performed to evaluate carcinogenic potential.Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.Long-term animal studies have not been performed to evaluate the carcinogenic potential of fluocinolone acetonide.. MutagenesisEight in vitro mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below: Salmonella/Microsome Test (Negative)E. coli DNA Repair Assay (Negative) Mouse Lymphoma Cell Forward Mutation Assay (Positive)Chinese Hamster V79 Cell HGPRT Test (Negative)Syrian Hamster Embryo Cell Transformation Assay (Negative)Saccharomyces cerevisiae Point Mutation Assay (Negative) Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative) Rat Hepatocyte DNA Repair Assay (Positive)Thus, of the tests were positive, but results of the following in vivo test systems gave negative results: Rat Hepatocyte DNA Repair AssayMicronucleus Test (Mice)Dominant Lethal Test (Mice)Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide. Some corticosteroids have been found to be genotoxic.. Salmonella/Microsome Test (Negative). E. coli DNA Repair Assay (Negative) Mouse Lymphoma Cell Forward Mutation Assay (Positive). Chinese Hamster V79 Cell HGPRT Test (Negative). Syrian Hamster Embryo Cell Transformation Assay (Negative). Saccharomyces cerevisiae Point Mutation Assay (Negative) Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative) Rat Hepatocyte DNA Repair Assay (Positive). Rat Hepatocyte DNA Repair Assay. Micronucleus Test (Mice). Dominant Lethal Test (Mice). Impairment of FertilityNo reproduction toxicity studies were conducted with Ciprofloxacin and Fluocinolone Acetonide Otic Solution. Absorption of ciprofloxacin and fluocinolone acetonide following otic administration of Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the recommended dosage is negligible see Clinical Pharmacology (12.3) ].

OVERDOSAGE SECTION.

10 OVERDOSAGE. Due to the characteristics of this preparation, no toxic effects are to be expected with an otic overdose of Ciprofloxacin and Fluocinolone Acetonide Otic Solution.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL 0.25 mL Vial Pouch Carton. NDC 42195-128-14 Rx Only Ciprofloxacin 0.3% and Fluocinolone Acetonide 0.025% Otic solutionSterile Preservative-free FOR USE IN THE EAR ONLYContents: 14 vials 0.25 mL each (Deliverable volume) Xspire Pharma, LLCSalvat. PRINCIPAL DISPLAY PANEL 0.25 mL Vial Pouch Carton.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Ciprofloxacin and Fluocinolone Acetonide Otic Solution has been studied in patients as young as months in adequate and well-controlled clinical trials. No major differences in safety and effectiveness have been observed between adult and pediatric patients see Indications and Usage (1) and Dosage and Administration (2)].

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. In two studies in children with AOMT aged >= months to 12 years, blood samples were taken in subgroups of 16 and 14 patients, at Visit (prior to the first dose) and Visit (within and hours after the last dose) respectively, to determine the plasma concentrations of ciprofloxacin and/or fluocinolone acetonide following administration of Ciprofloxacin and Fluocinolone Acetonide Otic Solution at the recommended dosage regimen of 0.25 mL twice daily. Pharmacokinetic (PK) analysis resulted in only sample showing detectable concentration of ciprofloxacin in plasma of 3.0 mcg/L after days of treatment, and no detectable concentrations in plasma of fluocinolone acetonide were observed. However, the sample with detectable ciprofloxacin concentrations was from patient who had bilateral AOMT (protocol deviation because all patients participating in the PK study were to have unilateral otorrhea) and who received treatment in both ears with ciprofloxacin 0.3% otic solution, the active comparator.

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryCiprofloxacin and Fluocinolone Acetonide Otic Solution is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see Clinical Pharmacology (12.3)].

SPL UNCLASSIFIED SECTION.

5.1Hypersensitivity Reactions. Ciprofloxacin and Fluocinolone Acetonide Otic Solution should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria and itching. Serious acute hypersensitivity reactions may require immediate emergency treatment.

STORAGE AND HANDLING SECTION.

StorageStore at 20-25C (68-77F); excursions permitted to 15-30C (59-86F) [see USP Controlled Room Temperature]. Protect from light; store unused vials in pouch and discard days after opening the pouch. Do not open until ready to use. Discard vial after use.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Risk SummaryCiprofloxacin and Fluocinolone Acetonide Otic Solution is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see Clinical Pharmacology (12.3)]. 8.2 Lactation. Risk SummaryCiprofloxacin and Fluocinolone Acetonide Otic Solution is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide see Clinical Pharmacology (12.3) ]. 8.4 Pediatric Use. Ciprofloxacin and Fluocinolone Acetonide Otic Solution has been studied in patients as young as months in adequate and well-controlled clinical trials. No major differences in safety and effectiveness have been observed between adult and pediatric patients see Indications and Usage (1) and Dosage and Administration (2)]. 8.5 Geriatric Use. Clinical studies of Ciprofloxacin and Fluocinolone Acetonide Otic Solution did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Hypersensitivity: Discontinue use at the first appearance of skin rash or any other sign of hypersensitivity. 5.1) Potential for Microbial Overgrowth: Prolonged use may result in the overgrowth of non-susceptible bacteria and fungi. If such infections occur, discontinue use and institute alternative therapy. 5.2) Hypersensitivity: Discontinue use at the first appearance of skin rash or any other sign of hypersensitivity. 5.1) Potential for Microbial Overgrowth: Prolonged use may result in the overgrowth of non-susceptible bacteria and fungi. If such infections occur, discontinue use and institute alternative therapy. 5.2) 5.1Hypersensitivity Reactions. Ciprofloxacin and Fluocinolone Acetonide Otic Solution should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria and itching. Serious acute hypersensitivity reactions may require immediate emergency treatment.. 5.2Potential for Microbial Overgrowth with Prolonged Use. Prolonged use of Ciprofloxacin and Fluocinolone Acetonide Otic Solution may result in overgrowth of non-susceptible bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.. 5.3Continued or Recurrent Otorrhea. If otorrhea persists after full course of therapy, or if two or more episodes of otorrhea occur within months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or tumor.